Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.
about
Pharmacology and physiology of gastrointestinal enteroendocrine cellsPharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisCalcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Etelcalcetide: First Global Approval.Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.Etelcalcetide for the treatment of secondary hyperparathyroidism.Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.Formulary Drug Review: Etelcalcetide.
P2860
Q26799380-289DE093-C2D4-4F52-ABD1-B29C1EC7359AQ37595124-2E66DA63-4577-4EC3-9D05-13D26E1CD0ADQ38576402-C9256BA7-0969-4BE9-AC89-CFC940FAC8E0Q38784143-765D5B4A-E2DE-4779-9A74-9BEF7AA888BAQ38828618-9495A1C0-1189-44CB-9508-266A0C49AD2AQ39024226-EA5057B1-2FDD-4761-9089-6D9714143373Q39034625-ED697A3C-4E88-4971-AA7E-20CD63A0027EQ39170853-1A27EE02-D857-4833-882C-399208C93ED7Q39379162-8EA15BD2-2669-4628-8C48-AA0BCF017DABQ47220207-BE9BAEA1-22C0-4F51-80BE-9E8184379B9EQ49166621-0642B913-F884-4D59-8B4F-9091F4852968Q49332215-36D1E703-36EB-4456-BDBB-62A50DAC8852Q49587355-932D4C0E-04A5-4DF9-BD2A-4CA977FFD263
P2860
Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Population pharmacokinetics an ...... oidism receiving hemodialysis.
@en
type
label
Population pharmacokinetics an ...... oidism receiving hemodialysis.
@en
prefLabel
Population pharmacokinetics an ...... oidism receiving hemodialysis.
@en
P2093
P2860
P356
P1476
Population pharmacokinetics an ...... oidism receiving hemodialysis.
@en
P2093
Mita Kuchimanchi
Murad Melhem
P2860
P304
P356
10.1002/JCPH.460
P577
2015-02-18T00:00:00Z